Recent Updates
Recently added Catalysts
ALKS Positive Sentiment

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research

Tuesday, October 13, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alkermes plc announced its participation in the European Sleep Research Society’s 28th Congress, Sleep Europe 2026, where it will present new data on LUMRYZ® and other sleep medicine research. The event will take place from October 20-23, 2026, in Maastricht, Netherlands. This underscores Alkermes' leadership in the field.

Market Sentiment Analysis

POSITIVE FACTORS

  • Alkermes is showcasing its leadership in sleep medicine research.
  • The presentation includes new data on LUMRYZ®.
  • The event highlights Alkermes' commitment to advancing sleep medicine.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+29%
120-day peak, hindsight
Typical move
2.8%
average across 7 past catalysts
Lead asset
ALKS 7290
Phase 2 · Attention Deficit Disorder With Hyperactivity (ADHD)

Full Press Release Details

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the European Sleep Research Society’s (ESRS) 28th Congress, Sleep Europe 2026, taking place Oct. 20-23, 2026 in Maastricht, the Netherlands. The company will present new data related to LUMRYZ® (sodium oxybate) extended-release oral suspension, now part of Alkermes’ sleep portfolio following the acquisition

Frequently Asked Questions

What will Alkermes present at Sleep Europe 2026?

Alkermes will present two oral presentations and six posters on its sleep medicine research.

When is Sleep Europe 2026 taking place?

Sleep Europe 2026 will occur from October 20-23, 2026.

Where will Sleep Europe 2026 be held?

The congress will be held in Maastricht, the Netherlands.

What is LUMRYZ®?

LUMRYZ® is an extended-release oral suspension of sodium oxybate.

ShareAdd on Google
Tags: ALKS Alkermes LUMRYZ sleep medicine ESRS sodium oxybate
Last updated: Oct 13, 2026

Biotech snapshot

Cash runway
$691M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALKS 7290Phase 2
Attention Deficit Disorder With Hyperactivity (ADHD) →

Catalyst track record

+29%
best trade around ALKS's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for ALKS.

See every catalyst's timing & PoA →